Cargando…
Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Background: First-line Helicobacter pylori (H. pylori) treatments have been relatively well evaluated; however, it remains necessary to identify the most effective rescue treatments. Our aim was to assess the effectiveness and safety of H. pylori regimens containing rifabutin. METHODS: International...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949410/ https://www.ncbi.nlm.nih.gov/pubmed/35329984 http://dx.doi.org/10.3390/jcm11061658 |
_version_ | 1784674889421029376 |
---|---|
author | Nyssen, Olga P. Vaira, Dino Saracino, Ilaria Maria Fiorini, Giulia Caldas, María Bujanda, Luis Pellicano, Rinaldo Keco-Huerga, Alma Pabón-Carrasco, Manuel Oblitas Susanibar, Elida Di Leo, Alfredo Losurdo, Giuseppe Pérez-Aísa, Ángeles Gasbarrini, Antonio Boltin, Doron Smith, Sinead Phull, Perminder Rokkas, Theodore Lamarque, Dominique Cano-Català, Anna Puig, Ignasi Mégraud, Francis O’Morain, Colm Gisbert, Javier P. |
author_facet | Nyssen, Olga P. Vaira, Dino Saracino, Ilaria Maria Fiorini, Giulia Caldas, María Bujanda, Luis Pellicano, Rinaldo Keco-Huerga, Alma Pabón-Carrasco, Manuel Oblitas Susanibar, Elida Di Leo, Alfredo Losurdo, Giuseppe Pérez-Aísa, Ángeles Gasbarrini, Antonio Boltin, Doron Smith, Sinead Phull, Perminder Rokkas, Theodore Lamarque, Dominique Cano-Català, Anna Puig, Ignasi Mégraud, Francis O’Morain, Colm Gisbert, Javier P. |
author_sort | Nyssen, Olga P. |
collection | PubMed |
description | Background: First-line Helicobacter pylori (H. pylori) treatments have been relatively well evaluated; however, it remains necessary to identify the most effective rescue treatments. Our aim was to assess the effectiveness and safety of H. pylori regimens containing rifabutin. METHODS: International multicentre prospective non-interventional European Registry on H. pylori Management (Hp-EuReg). Patients treated with rifabutin were registered in AEG-REDCap e-CRF from 2013 to 2021. Modified intention-to-treat and per-protocol analyses were performed. Data were subject to quality control. Results: Overall, 500 patients included in the Hp-EuReg were treated with rifabutin (mean age 52 years, 72% female, 63% with dyspepsia, 4% with peptic ulcer). Culture was performed in 63% of cases: dual resistance (to both clarithromycin and metronidazole) was reported in 46% of the cases, and triple resistance (to clarithromycin, metronidazole, and levofloxacin) in 39%. In 87% of cases rifabutin was utilised as part of a triple therapy together with amoxicillin and a proton-pump-inhibitor, and in an additional 6% of the patients, bismuth was added to this triple regimen. Rifabutin was mainly used in second-line (32%), third-line (25%), and fourth-line (27%) regimens, achieving overall 78%, 80% and 66% effectiveness by modified intention-to-treat, respectively. Compliance with treatment was 89%. At least one adverse event was registered in 26% of the patients (most frequently nausea), and one serious adverse event (0.2%) was reported in one patient with leukopenia and thrombocytopenia with fever requiring hospitalisation. Conclusion: Rifabutin-containing therapy represents an effective and safe strategy after one or even several failures of H. pylori eradication treatment. |
format | Online Article Text |
id | pubmed-8949410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89494102022-03-26 Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) Nyssen, Olga P. Vaira, Dino Saracino, Ilaria Maria Fiorini, Giulia Caldas, María Bujanda, Luis Pellicano, Rinaldo Keco-Huerga, Alma Pabón-Carrasco, Manuel Oblitas Susanibar, Elida Di Leo, Alfredo Losurdo, Giuseppe Pérez-Aísa, Ángeles Gasbarrini, Antonio Boltin, Doron Smith, Sinead Phull, Perminder Rokkas, Theodore Lamarque, Dominique Cano-Català, Anna Puig, Ignasi Mégraud, Francis O’Morain, Colm Gisbert, Javier P. J Clin Med Article Background: First-line Helicobacter pylori (H. pylori) treatments have been relatively well evaluated; however, it remains necessary to identify the most effective rescue treatments. Our aim was to assess the effectiveness and safety of H. pylori regimens containing rifabutin. METHODS: International multicentre prospective non-interventional European Registry on H. pylori Management (Hp-EuReg). Patients treated with rifabutin were registered in AEG-REDCap e-CRF from 2013 to 2021. Modified intention-to-treat and per-protocol analyses were performed. Data were subject to quality control. Results: Overall, 500 patients included in the Hp-EuReg were treated with rifabutin (mean age 52 years, 72% female, 63% with dyspepsia, 4% with peptic ulcer). Culture was performed in 63% of cases: dual resistance (to both clarithromycin and metronidazole) was reported in 46% of the cases, and triple resistance (to clarithromycin, metronidazole, and levofloxacin) in 39%. In 87% of cases rifabutin was utilised as part of a triple therapy together with amoxicillin and a proton-pump-inhibitor, and in an additional 6% of the patients, bismuth was added to this triple regimen. Rifabutin was mainly used in second-line (32%), third-line (25%), and fourth-line (27%) regimens, achieving overall 78%, 80% and 66% effectiveness by modified intention-to-treat, respectively. Compliance with treatment was 89%. At least one adverse event was registered in 26% of the patients (most frequently nausea), and one serious adverse event (0.2%) was reported in one patient with leukopenia and thrombocytopenia with fever requiring hospitalisation. Conclusion: Rifabutin-containing therapy represents an effective and safe strategy after one or even several failures of H. pylori eradication treatment. MDPI 2022-03-16 /pmc/articles/PMC8949410/ /pubmed/35329984 http://dx.doi.org/10.3390/jcm11061658 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nyssen, Olga P. Vaira, Dino Saracino, Ilaria Maria Fiorini, Giulia Caldas, María Bujanda, Luis Pellicano, Rinaldo Keco-Huerga, Alma Pabón-Carrasco, Manuel Oblitas Susanibar, Elida Di Leo, Alfredo Losurdo, Giuseppe Pérez-Aísa, Ángeles Gasbarrini, Antonio Boltin, Doron Smith, Sinead Phull, Perminder Rokkas, Theodore Lamarque, Dominique Cano-Català, Anna Puig, Ignasi Mégraud, Francis O’Morain, Colm Gisbert, Javier P. Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) |
title | Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) |
title_full | Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) |
title_fullStr | Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) |
title_full_unstemmed | Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) |
title_short | Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) |
title_sort | experience with rifabutin-containing therapy in 500 patients from the european registry on helicobacter pylori management (hp-eureg) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949410/ https://www.ncbi.nlm.nih.gov/pubmed/35329984 http://dx.doi.org/10.3390/jcm11061658 |
work_keys_str_mv | AT nyssenolgap experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT vairadino experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT saracinoilariamaria experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT fiorinigiulia experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT caldasmaria experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT bujandaluis experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT pellicanorinaldo experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT kecohuergaalma experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT paboncarrascomanuel experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT oblitassusanibarelida experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT dileoalfredo experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT losurdogiuseppe experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT perezaisaangeles experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT gasbarriniantonio experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT boltindoron experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT smithsinead experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT phullperminder experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT rokkastheodore experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT lamarquedominique experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT canocatalaanna experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT puigignasi experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT megraudfrancis experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT omoraincolm experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg AT gisbertjavierp experiencewithrifabutincontainingtherapyin500patientsfromtheeuropeanregistryonhelicobacterpylorimanagementhpeureg |